Biologics: China's new wave of innovation

Apr 23, 2015 Tags: Biotech Drug development Next Generation Companies

China has identified biologics innovation as a major driver for its biopharmaceutical industry and is actively promoting and funding the development of novel biologics as well as biosimilars. In a recent study, ChinaBio® identified nearly 100 antibody companies in China developing monoclonal antibodies, antibody drug conjugates and other related technologies, and there are many other programs underway at China's top universities and institutes. 

Moderator: Steve Yang, PhD – WuXi AppTec